33 results
424B5
TRML
Tourmaline Bio Inc
26 Jan 24
Prospectus supplement for primary offering
4:08pm
an innovative method of allogeneic hematopoietic stem cell transplantation (“allo-HSCT”) that we believe has the potential to transform the standard
424B5
TRML
Tourmaline Bio Inc
24 Jan 24
Prospectus supplement for primary offering
9:20pm
COMPANY
Overview
We are a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation
8-K
EX-99.1
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
;
establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid
8-K
EX-99.1
ug6xe
17 Oct 23
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
6:35pm
425
idvphdsilsnf8fuj59
10 Oct 23
Business combination disclosure
12:00am
8-K
EX-99.1
svdgy9r
6 Oct 23
Talaris Therapeutics Declares Special Dividend
5:30pm
424B3
p9bztys0 15z0fies98
15 Sep 23
Prospectus supplement
6:31am
S-4/A
fax8t 8sndgke3jmn488
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
ud4qelp0 8xisa3
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
dfzv5bj
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-99.1
r4xl9ue9u5bs3a
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am
8-K
EX-99.1
0163mbw bwfhh4
30 May 23
Talaris Therapeutics Announces Leadership Transition
4:51pm